NR5A2 and inflammation: The lower expression levels of LRH-1 in immune cells compared with intestinal tissue may shed a light in a possible therapeutic scenario in which low transient dose of LRH-1 inhibitors selectively delivered to immune cells could be helpful to contrast acute episodes of intestinal inflammation [87] without interfering with the highly expressed intestinal LRH-1, which in contrast confers an anti-inflammatory protection via its glucocorticoids synthesis function.